Antibiotics

>

Latest News

Recce Pharmaceuticals Targets Diabetic Foot Infections With First-in-Class Synthetic Anti-Infective
Recce Pharmaceuticals Targets Diabetic Foot Infections With First-in-Class Synthetic Anti-Infective

October 9th 2025

The company is advancing R327G, a novel synthetic anti-infective for diabetic foot infections, through a phase 3 clinical trial in Indonesia, marking a major step toward the first new anti-infective class approval in over 40 years.

Staphylococcus aureus Bloodstream Infections: Persistent Challenges and Emerging Therapeutic Opportunities
Staphylococcus aureus Bloodstream Infections: Persistent Challenges and Emerging Therapeutic Opportunities

October 5th 2025

Chemical Compound Supercharges Antibiotics to Fight Chronic Wound Infections
Chemical Compound Supercharges Antibiotics to Fight Chronic Wound Infections

October 3rd 2025

Addressing Resistance to Pathogens Such as NDM-CRE Through the Lens of Antimicrobial Development
Addressing Resistance to Pathogens Such as NDM-CRE Through the Lens of Antimicrobial Development

October 3rd 2025

Phase 3 Trial Begins for Topical Gel for Diabetic Foot Infections
Phase 3 Trial Begins for Topical Gel for Diabetic Foot Infections

October 2nd 2025

Video Series
Video Interviews
Podcasts

More News

© 2025 MJH Life Sciences

All rights reserved.